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Abstract: Non-medical use of prescription drugs 
(NMUPD) is increasing among the general popula-
tion, particularly among teenagers and young adults. 
Although prescription drugs are considered safer than 
illicit street drugs, NMUPD can lead to detrimental con-
sequences. The aim of the present study was to inves-
tigate the relationship between drug use (NMUPD on 
the one side, illicit street drugs on the other side) with 
mental health issues and then compare these associa-
tions. A representative sample of 5719 young Swiss men 
aged around 20  years filled in a questionnaire as part 
of the ongoing baseline Cohort Study on Substance Use 
Risk Factors (C-SURF). Drug use (16 illicit street drugs 
and 5 NMUPDs, including sleeping pills, sedatives, pain 
killers, antidepressants, stimulants) and mental health 
issues (depression, SF12) were assessed. Simple and 
multiple linear regressions were employed. In simple 
regressions, all illicit and prescription drugs were asso-
ciated with poorer mental health. In multiple regres-
sions, most of the NMUPDs, except for stimulants, were 
significantly associated with poorer mental health and 
with depression. On the contrary, the only associations 
that remained significant between illicit street drugs and 
mental health involved cannabis. NMUPD is of growing 
concern not only because of its increasing occurrence, 
but also because of its association with depression 
and mental health problems, which is stronger than 
the association observed between these problems and 
illicit street drug use, excepted for cannabis. Therefore, 
NMUPD must be considered in screening for substance 
use prevention purposes.
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Introduction
Prescription drugs are fundamental to the treatment of 
pain and psychiatric disorders such as depression or 
anxiety. Unfortunately, they can also cause abuse and 
dependency (1, 2), and this kind of use constitutes a criti-
cal public health concern (3). Non-medical use of pre-
scription drugs (NMUPD) has been defined as the use of a 
prescription drug i) without a doctor’s prescription, ii) for 
a longer period than prescribed, iii) for other reasons than 
those for which it was prescribed, or iv) in doses higher 
than those recommended (3–5). The purpose of use can 
be recreational (getting high, euphoric or intoxicated) or 
self-medication (5–7). Most studies took place in the U.S., 
and no comparison with other drug use has been inves-
tigated. The current study compared NMUPD and illicit 
street drugs in Switzerland.
NMUPD is of growing concern for several reasons. 
First, NMUPD has been shown in the U.S. to be the the 
second most common type of drug use after marijuana 
among teenagers and young adults (8–10). Second, 
NMUPD is increasing, particularly among young popu-
lations (11). For example, NMUPD increased by 67% 
in the U.S. between 1991–1992 and 2001–2002 (12), and 
is growing faster than marijuana use (10, 13). Thus, 
NMUPD did not seem to be used only among heavy 
substance users. Third, prescription drugs are easier 
to obtain than illicit street drugs (14, 15). People also 
tend to think that prescription drugs are safer than 
illicit street drugs (7, 14, 16). However, many studies that 
looked at the association between NMUPD and mood or 
personality disorders showed that NMUPD is associated 
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with detrimental effects, such as cognitive deficit and 
mood disorders (e.g., depression, accidental overdoses, 
and psychiatric disorders) as well as physical problems 
(e.g., organ damage), and other substance use disorders 
(2, 12, 15–22). These results seemed to be inconsistent 
with the belief that NMUPD are safer than illicit street 
drugs and that prescription drugs are not “really drugs” 
(23). However, no study has yet to compare the respec-
tive associations between NMUPD and illicit street drugs 
on the one hand and mental health issues on the other 
hand.
Therefore, the aim of this study was to investigate 
the relationship between drug use (illicit street drugs 
and NMUPD) and mental health issues (depression and 
mental health problems, i.e., sadness, nervousness, and 
depression). We aimed to find out which association was 
higher. A total of 16 illicit street drugs, including cannabis, 
and five types of NMUPD (sleeping pills, sedatives, pain 
killers, antidepressants, and stimulants) were analyzed. 
Moreover, this study aimed to provide further insights 
regarding NMUPD in another country (Switzerland) than 
the U.S. and Canada, where most previous studies have 
been conducted (15).
Materials and methods
Sample and data collection
The data used in this study form part of the Cohort Study on 
Substance Use Risk Factors (C-SURF). C-SURF is a longitudinal 
study, which is taking place in Switzerland and is designed to 
assess substance use patterns and related consequences in Swiss 
young men. Illicit drug use, NMUPD, and mental health issues 
were collected at the same time during the baseline assessment 
of the C-SURF study. Enrolment took place between August 23, 
2010 and November 15, 2011 at three (of six) army recruitment 
centers located in Lausanne (French-speaking) and Windisch and 
Mels (German-speaking). These centers cover 21 of 26 cantons in 
Switzerland, including all French-speaking cantons. In Switzer-
land, army recruitment is mandatory, so the study was largely 
representative of all young Swiss men. The study obtained ethi-
cal approval by the Ethics Committee for Clinical Research of the 
Lausanne University Medical School and followed the Helsinki 
declaration.
Altogether, of the 13,245 conscripts informed about the study, 
7563 gave written consent to participate and 5990 filled in the base-
line questionnaire. Missing values were listwise deleted, so the 
study ultimately included 5719 participants (95.5% of the sample). 
More information about sampling and non-response can be found 
in Studer et  al. (24). Non-respondents were more often substance 
users, but the differences between respondents and non-respond-
ents were small and may be significant only because of the large 
sample size.
Measures
Participants who consented to participate were invited by mail or 
email to fill in a paper and pen or an online questionnaire, according 
to the preference they indicated in the written consent. The question-
naire lasted approximately 1 h and included topics such as sociode-
mographic background, health, family background, substance use 
(alcohol, tobacco, cannabis, other illicit drugs, NMUPD), personality 
and leisure time activities, and sexuality. Participants answered first 
health issues, followed by questions on substance use.
NMUPD
NMUPD was assessed with five questions about the use of prescrip-
tion drugs without a doctor’s prescription or for reasons other than 
those indicated during the past 12 months. The answers were col-
lected on an 8-point scale (never, once, 2–3 times a year, 4–9 times 
a year, 1–2 times a month, 3–4 times a month, 2–3 times a week, and 
4 times a week or more) and coded dichotomously as “used” or “not 
used”. The prescription drugs and associated examples were as fol-
lows: i) sleeping pills (e.g., benzodiazepine (Dalmadorm®, Rohyp-
nol®, Halcion®), barbiturate, chloralhydrate (Nervifène®), zopiclon, 
zolpidem (Imovane®, Stilnox®)); ii) tranquilizers (e.g., benzodiaz-
epine (Valium®, Xanax®, Librax®, Temesta®, Normison®, Demetrin®, 
Dalmadorm®) and muscle relaxing drugs); iii) strong painkillers 
(e.g., buprenorphine (Tamgesic®), codeine (Benylin®), opium-based 
products (Fentanyl®, Hydrocodon®, Jurnista®, Palladon®, Targin®, 
Oxycontin®, Vicodin®, Dilaudid®) and DXM (Bexin®), but over-
the-counter painkillers such as Aspirin® and Paracetamol® were 
excluded); iv) antidepressants (Remeron®, Fluoxetine®, Citalopram®, 
Trimin®); and v) stimulants (e.g. amphetaminsulphate (Aderall®), 
atomoxetine (Strattera®), methylphenidate (Ritalin®)).
Illicit street drugs
The prevalence rate of illicit street drugs during the past 12 months 
was measured for 16 drugs. The drugs were as follows: i) cannabis 
(hashish, marihuana, grass); ii) hallucinogens, magic mushrooms, 
psilocybin, peyote, mescaline; iii) other hallucinogens (LSD, PCP/
Angeldust, 2-CB, 2-CI); iv) salvia divinorum; v) speed; vi) ampheta-
mine, methamphetamine, amphetaminsulfate (e.g., Dexedrine, 
Benzedrin); vii) crystal meth (Ice); viii) poppers (Amylnitrit, Butylni-
trit); ix) solvent sniffing (e.g., glue, solvent and gas such as benzin, 
ether, toulol, trichloräthylen, nitrous oxide); x) ecstasy, MDMA; xi) 
cocaine, crack, freebase; xii) heroin; xiii) ketamine (Special K), DXM; 
xiv) GHB/GBL/I-4 Butandiol (BDB); xv) chemicals used in research 
(e.g., mephedrone, butylone and methedrone); and xvi) spices or 
similar substances (synthetic marijuana). The drugs were aggre-
gated into five subclasses: 1) cannabis; 2) hallucinogens, including 
magic mushrooms, other hallucinogens, salvia divinorum and spice; 
3) uppers, including speed, ecstasy, cocaine and amphetamine; 4) 
sniffed drugs, including poppers and solvents; and 5) “hard” drugs, 
including crystal meth, heroin, ketamine and chemicals used in 
research. Each subclass was collected on a 3-point scale (never, 1–3 
times, 4 times or more) and coded dichotomously “used” or “non-
used”. Participants indicated first their illicit street drug use, and 
then their NMUPD.
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Table 1 Prevalence rates of illicit street drug and NMUPD use 
during the past 12 months.
  % of users
Illicit street drugs  
 Cannabis   30.5
 Hallucinogens   5.0
 “Hard” drugs   1.2
 Sniffed drugs   4.2
 Uppers   5.6
Non-medical use of prescription drugs  
 Antidepressants   0.9
 Anxiolytics   2.6
 Painkillers   6.8
 Sleeping pills   3.0
 Stimulants   1.9
Mental health issues
Mental health issues were assessed with depression and mental 
health problems. The Major (ICD-10) Depressive Inventory (WHO-
MDI) was used to determine the level of depression (25, 26). It com-
prises 10 criteria, with two criteria being assessed by two questions 
(restless vs. subdued and increased vs. reduced appetite, where the 
higher score of the two alternatives for each criterion was used). A 
six-point scale ranging from “never” (0) to “all the time” (5) was 
used, and a total score from 0 to 30 was computed (Cronbach’s 
α = 0.91). Mental health was assessed with six questions from the 
12-item Short-Form Health Survey (SF-12) [SF-12; (27)], which deals 
with sadness, nervousness, and depression. The total score was com-
puted according to the authors’ recommendations (with a standard-
ized mean of 50, wherein the lower values reflect bad mental health, 
Cronbach’s α = 0.61). Participants were asked to complete SF12 first, 
and then WHO-MDI.
Covariates
Demographic covariates included language (French- or German-
speaking), urbanicity (urban area: more than 10,000 inhabit-
ants; rural area:  < 10,000 inhabitants), perceived family income 
(“below-average income”, “average income”, “above-average 
income”) and completed education (primary: 9 years of schooling; 
secondary: around 12 years; tertiary: 13 years or more, including 
university).
Statistical analyses
First, descriptive statistics were computed to investigate the preva-
lence rate of NMUPD. Linear regressions were then performed to test 
the relationship between drug use and mental health issues, compar-
ing illicit street drugs and NMUPD’s associations with mental health 
issues. Depression and mental health were successively considered as 
outcome variables, while illicit street drug and NMUPD were consid-
ered dichotomic exposure variables. Simple linear regressions were 
performed for each of the five subclasses if illicit street drugs and five 
NMUPD for the two outcome variables. Multiple linear regressions, 
including all the illicit and NMUPD, were performed for the two out-
come variables. Multicollinearity was checked to avoid reducing the 
predictive power of the model. Simple and multiple regressions were 
performed to test the individual and combined influence of each drug 
on mental health as well as to isolate the relationship between each 
drug used and mental health, accounting for the other drugs. Indeed, 
one can suppose that the drugs share common variance and this 
covariance should be taken into account to properly reflect the rela-
tionship between drug use and mental health. All the models were 
tested with adjustment for demographic variables (adjusted models). 
Standardized regression slopes (β) were presented instead of raw 
slopes to permit comparability between different drugs (illicit street 
drugs and NMUPD) with a scale-free estimation (28). The standard-
ized slope could be considered as an effect-size index (28). A Bon-
ferroni-Holms correction was performed in post-hoc comparisons to 
keep the type I error rate at 5%. All the analyses were conducted with 
SPSS 20.
Results
Preliminary results
The participants’ mean age was 20.0  years (SD: 1.23), 
55.0% were French-speaking and 41.1% lived in urban 
areas. Most participants had completed primary education 
(48.4%, secondary: 26.0%; tertiary or higher: 25.5%) and 
only 14.3% had a family income below average (average: 
41.5%; above average: 44.1%). The average level of depres-
sion was low (mean = 7.0, SD = 7.2) as the average level of 
mental health problems (mean = 47.4, SD = 9.1).
The prevalence rates of drug use are illustrated in 
Table 1. The most prevalent illicit street drugs were can-
nabis (30.3%), followed by uppers (5.6%) and hallucino-
gens (5.0%). The most prevalent non-medical prescription 
drugs were painkillers (6.8%), followed by sleeping pills 
(3.0%) and anxiolytics (2.6%). Stimulants and antide-
pressants were less prevalent at rates of 1.9% and 0.9%, 
respectively.
Associations of mental health issues with 
NMUPD and illicit street drugs
The simple regressions showed that all the drugs were sig-
nificantly associated with mental health issues (Table 2). 
The use of the drug considered during the past 12 months 
was associated with poorer mental health (for increased 
depression, coefficients ranged between 0.080 and 0.163, 
while for decreased mental health, coefficients ranged 
between –0.056 and –0.131).
In multiple regressions, the comparisons showed that 
cannabis, sleeping pills, painkillers, antidepressants, 
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and anxiolytics were significantly associated with mental 
health issues (except for anxiolytics with SF12), whereas 
other illicit street drugs were never significantly associ-
ated with mental health issues (Table 3). Participants 
who reported higher levels of depression or mental health 
problems were more likely to be cannabis and non-med-
ical prescription drug users, with the exception of stim-
ulants, which were not associated with mental health. 
Mental health was not significantly associated with any 
other illicit street drug.
Table 2 Simple linear regressions of mental health (depression 
and SF12) on illicit drugs (illicit street drugs and NMUPD).
Variables   Depression   SF12
  β   p-Value   β   p-Value
Illicit street drugs        
 Cannabis   0.114   0.000   –0.116   0.000
 Hallucinogens   0.111   0.000   –0.078   0.000
 “Hard” drugs   0.125   0.000   –0.067   0.000
 Sniffed drugs   0.080   0.000   –0.056   0.000
 Uppers   0.107   0.000   –0.092   0.000
NMUPD        
 Antidepressants   0.159   0.000   –0.108   0.000
 Anxiolytics   0.162   0.000   –0.101   0.000
 Painkillers   0.126   0.000   –0.086   0.000
 Sleeping pills   0.163   0.000   –0.131   0.000
 Stimulants   0.123   0.000   –0.076   0.000
Notes: Adjusted standardized slopes (β), β standard errors (SE) and 
p-value (p) are given. A Bonferroni-Holm correction was applied.
Table 3 Multiple linear regressions of mental health (depression 
and SF12) on illicit drugs (illicit street drugs and NMUPD).
Variables   Depression   SF12
  β   p-Value   β   p-Value
Illicit street drugs        
 Cannabis   0.080   0.000   –0.093   0.000
 Hallucinogens   0.026   0.082   –0.005   0.759
 “Hard” drugs   0.036   0.060   0.004   0.772
 Sniffed drugs   0.022   0.098   –0.015   0.276
 Uppers   0.000   0.994   –0.027   0.080
Non-medical use of 
prescription drugs
       
 Antidepressants   0.073   0.000   –0.052   0.000
 Anxiolytics   0.073   0.000   –0.035   0.084
 Painkillers   0.056   0.001   –0.040   0.021
 Sleeping pills   0.078   0.000   –0.080   0.000
 Stimulants   0.028   0.176   –0.006   0.684
Notes: Adjusted standardized slopes (β) and p-value (p) are given. A 
Bonferroni-Holm correction was applied.
Discussion
Main findings
This study compared the associations of NMUPD and illicit 
street drug use with mental health issues (depression and 
mental health problems) within a sample of young Swiss 
men. It also attempted to determine whether one of these 
two kinds of drugs was associated with increased mental 
health issues. The study also provided further insights 
regarding NMUPD in countries other than the U.S. and 
Canada, where NMUPD has been most studied.
The prevalence rate for NMUPD and illicit street drug 
use during the previous 12  months indicated that can-
nabis was, by far, the most common drug used by the 
participants (30.3%). The second most used substance 
was painkillers (6.8%). This result is in accordance with 
previous studies that reported painkillers to be the most 
common NMUPD (15, 29–31), after cannabis use. The 
new epidemic observed in North America may then also 
affect Switzerland. Calming prescription drugs were more 
prevalent than stimulants (sleeping pills: 3.0%, anxiolyt-
ics: 2.6%), as was found in the U.S. in the “Monitoring the 
Future” study (31). By contrast, the most prevalent illicit 
street drugs other than cannabis were stimulants (5.6%) 
and hallucinogens (5.0%). Downers seemed to be more 
popular among prescription drugs and uppers among 
illicit street drugs.
Mental health issues were found to be differently 
associated with drug use when simple or multiple regres-
sions were performed. In simple regression, the use of 
each substance was associated with poorer mental health. 
However, when multiple regressions were performed, 
the only significant associations were for cannabis and 
NMUPD (except stimulants for depression and SF12, and 
anxiolytics for SF12). Cannabis use and NMUPD were 
associated with higher levels of mental health problems 
and depression than non-cannabis use or non-NMUPD. 
This means that the illicit street drugs other than canna-
bis and prescription stimulants showed no detrimental 
associations with mental health when their common vari-
ance with cannabis and NMUPD was eliminated. Even if 
illicit drugs other than cannabis were individually associ-
ated with poorer mental health, when all the substances 
were combined, cannabis and NMUPD were sufficient in 
explaining the relationship between drug use and mental 
health. This was due to the fact that the remaining and 
proper variance of illicit drugs other than cannabis was 
not significantly associated with mental health issues. 
The result was true even for the “hardest” illicit street 
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drugs, including heroin, ketamine or crystal meth. Users 
think that prescription drugs are safer than illicit street 
drugs (7, 14, 16). In relation to this, the results highlighted 
in this study showed that it was not the case. Interestingly, 
prescription stimulants showed a similar pattern as illicit 
street drugs, thus suggesting that prescription stimulants 
should be used similarly as illicit street drugs, whereas 
downers NMUPD were not. This could be because pre-
scription stimulants and illicit street drugs were used to 
get high and for recreational purposes, whereas downers 
NMUPD were used for the purpose of coping. However, 
more studies are needed, as motives of use were not inves-
tigated in the current study. Finally. cannabis was the 
only illicit street drug that showed significant associa-
tions with mental health issue. Previous findings showed 
that cannabis is harmful to health (32), and the result of 
this study, even if it did not access a causal relationship 
between cannabis use and mental health, is especially 
worrying given that cannabis is the most used illicit drug 
worldwide (33, 34).
Limitations
This study presents several limitations. The most criti-
cal is that this cross-sectional study did not allow the 
determination of causality, that is, whether NMUPD is a 
cause or a consequence of mental health issues This is 
a common limitation in studies on drug use (5, 16, 35). 
For example, antidepressants may be overused by people 
who are already depressed, so NMUPD may be a conse-
quence of depression and not a cause. However, irregular 
use of antidepressants is also associated with worsening 
depression (36, 37). Another limitation is the similarity 
between mental health issues and intoxication symp-
toms. Indeed, many symptoms of intoxication resemble 
the symptoms of mood disorders (8). Thus, it can be dif-
ficult to distinguish between “real” mental health issues 
and the effects of heavy use of non-medical prescription 
drugs. Nevertheless, the participants in our study were 
not heavy users.
Regarding stimulants, both illicit street drugs and 
prescription stimulants included similar components 
(for example, Dexedrine). Therefore, confusion may have 
occurred for these two subclasses of substances.
We do not know whether prescription drugs were used 
by our participants to get high or as self-medication. Thus, 
further research is needed to highlight the prevalence rate 
and effect of NMUPD in relation to reasons for this use, as 
well as to investigate the difference between downer pre-
scription drugs and prescription stimulants. Finally, the 
study focused exclusively on young Swiss men and is not 
representative of the general population. However, sex 
effects on NMUPD are well documented (3, 12, 15, 16, 18, 
21) and the enrolment procedure in army centers enables a 
representative sample not exclusively composed of college 
or high school students.
Conclusion
This study indicated that NMUPD could be just as wor-
rying as illicit street drug use. Indeed, NMUPD not only 
shows a high and increasing occurrence in Western coun-
tries, it is also strongly associated with mental health 
issues and such associations outstripped those of mental 
health issues with illicit street drugs. The findings sup-
ported the idea that NMUPD are not “safe drugs”, and 
preventive information and interventions may focus on 
this class of drugs, especially for NMUPDs that are highly 
addictive (opiates and sleeping pills).
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